SUMMARY In an attempt to define quantitatively the relation between left atrial size and atrial fibrillation, echocardiography was used to study 85 patients with isolated mitral valve disease, 50 patients with isolated aortic valve disease, and 130 patients with asymmetric septal hypertrophy. In all three groups of patients, atrial fibrillation was rare when left atrial dimension was below 40 mm (3 of 117 or 3%) but common when this dimension exceeded 40 mm (80 of 148 or 54%). In addition, when left atrial dimension exceeds 45 mm, cardioversion, while initially successful, is unlikely to produce sinus
SUMMARY In an attempt to define quantitatively the relation between left atrial size and atrial fibrillation, echocardiography was used to study 85 patients with isolated mitral valve disease, 50 patients with isolated aortic valve disease, and 130 patients with asymmetric septal hypertrophy. In all three groups of patients, atrial fibrillation was rare when left atrial dimension was below 40 mm (3 of 117 or 3%) but common when this dimension exceeded 40 mm (80 of 148 or 54%). In addition, when left atrial dimension exceeds 45 mm, cardioversion, while initially successful, is unlikely to produce sinus ATRIAL FIBRILLATION occurs in association with a variety of disease states. A particularly strong association is found both in patients with mitral valve disease, and in patients with asymmetric septal hypertrophy (ASH), with the onset of this arrhythmia often precipitating or exacerbating the symptoms and signs of congestive heart failure. [1] [2] [3] In addition, the development of atrial fibrillation markedly increases the risk of embolization, a complication that often is devastating or sometimes fatal. 4 Because rheumatic fever is the etiology of the mitral valve abnormalities in many patients with mitral valve disease, some investigators have suggested that atrial fibrillation is related to rheumatic involvement of the left atrial wall."
Others, however, have noted that patients with atrial fibrillation have a large left atrium and interpret this as evidence that atrial dilatation is in some way related to atrial fibrillation. ' 12, 13 Still others have suggested that age is an important factor influencing the development of atrial fibrillation. 9 These associations are important not only in understanding the pathophysiology of atrial fibrillation, but also have potentially important clinical and therapeutic implications. For instance, the embolic events that are a major complication of atrial fibrillation may occur at onset of the arrhythmia or shortly following conversion from atrial fibrillation to normal sinus rhythm.4-9, 14-1 Therefore, if a subgroup of patients in normal sinus rhythm could be identified who are at risk of developing atrial fibrillation, prophylactic anticoagulation and antiarrhythmic drugs might be used as a possible means of preventing fibrillationinduced emboli. In addition, if patients in atrial fibrillation could be identified who are unlikely to be maintained in sinus rhythm following cardioversion, attempts to convert the arrhythmia might be abandoned, thereby eliminating the risk of postcardioversion embolization.
Echocardiography has proven to be a valuable nonin-rhythm that can be maintained at least six months. These data suggest that left atrial size is an important factor in the development of atrial fibrillation and in determining the long term result of cardioversion. The pathophysiologic mechanism most consistent with this is that a chronic hemodynamic burden initially produces left atrial enlargement which in turn predisposes to atrial fibrillation. Only prospective studies will determine definitively whether these observations will be useful in decisions concerning prophylactic anticoagulation and elective cardioversion.
vasive tool for quantitatively assessing left atrial size.'7"'l In the present study, we used this technique to evaluate the association of left atrial size and the development of atrial fibrillation as well as the relation of left atrial size to the success or failure of cardioversion in patients with isolated mitral valve disease, asymmetric septal hypertrophy (ASH), and isolated aortic valve disease. In addition, we examined the prevalence of embolic complications in these same patients.
Methods

Patient Population
The study population consisted of 85 patients with isolated mitral valve disease (55 women, 30 men), 50 patients with isolated aortic valve disease (11 women, 39 men), and 130 patients with asymmetric septal hypertrophy (44 women, 86 men), in whom adequate echocardiograms were obtained during evaluation either in the outpatient clinic or the inpatient service of the National Heart and Lung Institute. The degree of functional impairment of the patients ranged from minimal to severe, and many of the latter required cardiac catheterization and operative intervention.
Echocardiographic Evaluation
The echocardiographic system used consists of an Ekoline 20A ultrasound unit, Honeywell 1856 Line Scan Recorder, Hewlett-Packard X-Y display, and a custom-built video amplifier. Echocardiographic studies were performed in every patient supine and in a basal state. In each patient with aortic valve disease, review of the echocardiograms failed to reveal evidence of mitral stenosis. In patients with asymmetric septal hypertrophy, the septal free-wall ratio (by definition) equaled or exceeded 1.3 The age at onset of atrial fibrillation is shown graphically in figure 5 for patients with isolated mitral valve disease and those with asymmetric septal hypertrophy. In eight patients, age at onset of atrial fibrillation could not be determined.
Left Atrial Dimension and Cardioversion
The relation between left atrial dimension, length of time in atrial fibrillation prior to cardioversion attempt, and the success or failure of DC cardioversion for nonoperated patients with either isolated mitral valve disease or asymmetric septal hypertrophy is shown in figure 6 . In this analysis, cardioversion was considered unsuccessful either if normal sinus rhythm was not achieved or if achieved, it was not maintained for at least six months. In some individuals, more than one cardioversion attempt was made. If any one of the multiple attempts produced normal sinus rhythm that was maintained for at least six months, the patient was con- Of the patients with asymmetric septal hypertrophy who embolized, nine of 11 (82%) at the time of echocardiographic study would have been classified by history as having either chronic (7) or paroxysmal (2) 
Discussion
The results of the present study support previous suggestions that the presence or absence of atrial fibrillation is closely related to both the degree of left atrial dilatation and the age of patients with isolated mitral valve disease. Our results also demonstrate a similar relation in patients with aortic valve disease and asymmetric septal hypertrophy (ASH), the latter observation indicating that rheumatic involvement of the atrial wall is not the primary etiologic factor in the development of atrial fibrillation. In addition, the data indicate that a quantitative estimation of left atrial size by echocardiography provides a relatively sharp numerical cutoff in left atrial dimension that separates patients in normal sinus rhythm from those with chronic or paroxysmal atrial fibrillation. Thus, atrial fibrillation was rare in patients with a left atrial dimension below 40 mm (3 of 117 or 3%) but common when this dimension exceeded 40 mm (80 of 148 or 54%, P < 0.01). Furthermore, in the subgroup of patients who were 40 years of age or older and who had left atrial dimension 45 mm or greater, atrial fibrillation occurred in 47 of 53 (89%) of those with isolated mitral valve disease, two of five (40%) of those with isolated aortic valve disease, and 21 of 24 (87%) of those with ASH. When patients falling outside this subgroup are considered, atrial fibrillation occurred in only two of 32 (6%) patients with isolated mitral valve disease, 0 of 45 patients with isolated aortic valve disease, and 11 of 106 (10%) patients with ASH. 277 VOL. 53, No. 2, FEBRUARY 1976 The relation between left atrial size and atrial fibrillation was not influenced by the specific type of mitral valve lesion in patients with isolated mitral valve disease or by the severity of left ventricular outflow obstruction for patients with asymmetric septal hypertrophy.
We believe these results have therapeutic application in that it may be possible with echocardiography to identify patients in sinus rhythm who are at high risk of developing atrial fibrillation. Since ten of 81 (12%) patients in the present series who had atrial fibrillation due to either isolated mitral valve disease or asymmetric septal hypertrophy had a history of an embolic event at the onset of the arrhythmia, either prophylactic anticoagulation, antiarrhythmic drugs, or both, might be considered in the management of a patient in normal sinus rhythm who appears to be in a subgroup at high risk of developing atrial fibrillation. The information obtained in the present study suggests that measurement of left atrial size by echocardiography may allow such a high risk group to be identified. Obviously, only a prospective trial can determine whether the potential benefit of a reduction in embolic events will be realized, and if it is, whether it will outweigh the hazards of drug therapy. Until such data are available, we presently recommend prophylactic anticoagulation to patients in sinus rhythm with either mitral valve disease or asymmetric septal hypertrophy if their left atrial dimension exceeds 40 mm and they are older than age 35 ( fig. 5) .
Moreover, although the embolic risk per patient year is greatest during the first six months after onset of atrial fibrillation (as indicated by previous studies on patients with mitral valve disease4 5' 7), the subsequent risk of an initial embolus is not inconsequential (table 1) . As a result, we also recommend anticoagulation therapy to a patient with established atrial fibrillation who has mitral valve disease or ASH, regardless of the length of time that atrial fibrillation has been present. The results of the present study also suggest that there may be a relation between left atrial size and the long-term success or failure of cardioversion. For instance, we found that although most patients achieved sinus rhythm during attempted cardioversion, relapse to atrial fibrillation was common; only six of 24 (25%) patients with isolated mitral valve disease and three of 13 (23%) patients with ASH maintained sinus rhythm for longer than six months ( fig. 6 ), a long-term cardioversion success rate consistent with that of previous studies16 22, 23 of patients with mitral valve disease.
Some investigators have suggested that the long-term success rate of cardioversion is low primarily when atrial fibrillation has been present for a prolonged duration prior to the cardioversion attempt.16 22, 23 The observation in the present study that none of the five patients with atrial fibrillation present for longer than one year was able to be cardioverted and maintained in sinus rhythm for longer than six months is consistent with that suggestion. However, in those patients in whom cardioversion was attempted within one year of onset of atrial fibrillation, we found that only six of 19 (32%) patients with isolated mitral valve disease and three of 13 (23%) patients with asymmetric septal hypertrophy were able to be cardioverted and maintained in sinus rhythm for at least six months. Since all these patients had a left atrial dimension exceeding 45 mm, it is conceivable that once moderate left atr/al dilatation occurs, maintenance of normal sinus rhythm for at least six months following cardioversion is relatively uncommon, even if cardioversion is attempted shortly after the onset of the arrhythmia.
In the 24 patients with mitral valve disease in whom DC cardioversion was attempted, no embolic events occurred, a finding consistent with the low embolic rates (1-3%) previously reported in patients with rheumatic heart disease.'4 16 However, emboli did occur in three of the 13 (23%) patients with ASH when DC cardioversion was performed, despite the fact that two of the three were adequately anticoagulated with warfarin at the time of cardioversion. Thus, patients with ASH appear to be particularly susceptible to embolization following cardioversion. In addition, it appears that patients with asymmetric septal hypertrophy who have a left atrial dimension of 50 mm or greater are a particularly vulnerable group; DC cardioversion was successful in achieving and maintaining sinus rhythm for at least six months in only one of ten (10%) patients in this group, while emboli occurred in three of the ten (30%) patients (three of 20 cardioversion attempts).
The strong association of left atrial size and atrial fibrillation in our study appears to indicate a cause and effect relation, a conclusion suggested by Probst et left atrial size in the patients with paroxysmal atrial fibrillation was normal prior to the first occurrence of the arrhythmia and that atrial dilatation was produced in these patients by the relatively short and infrequent paroxysms of atrial fibrillation they had experienced. In this regard, we were able to measure left atrial dimensions in three patients both before and after an episode of paroxysmal atrial fibrillation. In all three patients, no change in left atrial dimension was found. In addition, several patients without a history of atrial fibrillation had moderate left atrial enlargement indicating that atrial dilatation can be produced by a hemodynamic burden alone.
The pathophysiology of atrial fibrillation in patients with valvular heart disease or asymmetric septal hypertrophy that is best supported by our echocardiographic data and that we presently are using as a working hypothesis is outlined in figure 7 : a chronic hemodynamic burden initially produces atrial dilatation (and possibly structural damage to the atrial wall); atrial dilatation in turn increases the likelihood of the development of atrial fibrillation, perhaps through re-entrant mechanisms;24 once atrial fibrillation is present, atrial dilatation could progress as a consequence of either the continued hemodynamic burden, the loss of atrial systole, or both. Whether the mechanisms outlined in figure  7 will apply to the pathogenesis of atrial fibrillation that occurs in patients with other abnormalities (for example, thyrotoxicosis or ischemic heart disease) is unclear.
We should point out that we did not routinely perform coronary arteriography in our patients. Hence, it is not possible to exclude coronary artery disease as a possible factor in the pathogenesis of atrial fibrillation in some of our patients, particularly since patients in atrial fibrillation were usually older than 40 years of age. We do not believe, however, that coronary artery disease could have been a major precipitating factor, for several reasons. First, symptoms suggesting coronary artery disease are rare in patients with isolated mitral valve disease. Second, in our experience, most patients with asymmetric septal hypertrophy have normal coronary arteries as evidenced by both angiographic and necropsy findings. And finally, even in the unlikely possibility that many of our patients had unsuspected coronary disease, the prevalence of chronic or paroxysmal atrial fibrillation in coronary disease patients does not nearly approach the almost 90% prevalence of the arrhythmia that was found in patients above age 40 years who also had left atrial dilatation.
In conclusion, the results of the present investigation demonstrate a quantitative relation between atrial size, measured echocardiographically, and the presence or absence of atrial fibrillation. In addition, the data suggest that left atrial size may be an important factor in determining whether cardioversion will be successful in achieving and maintaining sinus rhythm for at least six months. Although these data suggest that the detection of left atrial dilatation by echocardiography may be useful in decisions concerning prophylactic anticoagulation, only a prospective study can determine whether the benefit of prophylactic therapy will outweigh the potential hazards.
